EGFR and non-small cell lung carcinoma: In NSCLC models, SH003 ± docetaxel exerts synergistic antitumor effects via EGFR/STAT3 blockade; while exosome-based metabolomic signatures are best positioned as exploratory predictive biomarkers rather than proximal effectors of response, pending prospective immune-functional validation [26,27].